معرفی
Prof. Dr. med. Georg Lenz is a Professor of Translational Oncology at the University of Münster, leading the Translational Oncology Unit at the University Hospital Münster. He combines clinical work in hematology/oncology with laboratory research on malignant lymphoma pathogenesis. His research focuses on molecular mechanisms driving lymphoma development, with emphasis on NF-κB, PI3K/AKT pathways, and tumor microenvironment interactions. Clinical efforts include translating discoveries into targeted therapies via clinical trials.
Education and career highlights include training at Ludwig-Maximilians University Munich, postdoctoral research in the U.S., and roles at Charité Berlin (2009–2014). His work bridges basic science and clinical practice, aiming to personalize cancer treatment through molecular profiling.
Research trends in his publications emphasize nanocarrier drug delivery systems, AI-driven diagnostics, and combination therapies targeting tumor vasculature. His team collaborates on clinical trials testing novel agents like L19TNF and tissue factor-based treatments.
Grants and advising: His lab receives support via the Cells-in-Motion Cluster of Excellence. Key collaborations involve imaging networks and clinical trials. The Lenz Lab focuses on lymphoma cell cultures, flow cytometry, and small hairpin RNA screens to identify therapeutic targets.
Future directions include advancing precision medicine approaches and optimizing targeted therapies for hematologic malignancies.
